Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
Silver's rally could be losing its shine after the precious metal reached its year-to-date high, futures experts warn.Futures Nowread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
As the first quarter comes to a close, three Bay Area life sciences companies have already gone public in 2018.
Google parent company Alphabet has had a stake in two of them.
The company's venture arm, GV (formerly known as Google Ventures), has backed nearly 60 healthcare-related companies since it raised its first fund in 2009, making it one of the most active Silicon Valley players in the space.
Those bets are starting to pay off: Five of GV's healthcare bets have gone public in the last year.
GV owned a large enough stake in four of them — 10 percent or more — to be required to report as an insider with the SEC.
The market value for the firm's combined ownership of those four companies is roughly $153 million, according to data from FactSet:
Here are the five companies, what they do, and when GV invested:
Spero Therapeutics, a biopharmaceutical company creating treatments for bacterial infections, started trading on the Nasdaq last fall and has a current market cap of $204.8 million.
GV led its Series C in March 2017 and its stake is now worth $15.79 million, according to FactSet.
Arsanis, which is working on antibody immunotherapies for infectious diseases, went public in November of last year and has a market cap of $327.2 million. GV invested in its Series D in April 2017 and its stake is worth $10.62 million, according to FactSet.
Arcus Bioscience, which develops cancer immunotherapies, went public in March and has a market cap of $657 million.
GV first invested in Arcus' Series B in 2016 and again in its Series C in 2017, and its stake is worth $80.9 million, according to FactSet.
ARMO Biosciences fights cancer through immunotherapy. It went public in January 2018 has a market cap of $1.1 billion. GV invested in its Series C as well as its Series C-1 in 2016 and 2017 respectively, and its stake is currently worth $45.14 million.
Denali Therapeutics creates therapies for neurodegenerative diseases like Alzheimer's and Parkinson's and went public in December 2017 and currently has a market cap of $1.86 billion.
There's a good chance 2018 will bring more excitement: Nasdaq's head of healthcare listings recently predicted that biotech M&A will be hot this year and that we could see 30+ total biotech IPOs.
GV portfolio company 23andMe is expected to file before the end of the year.